Over 100 pharmaceutical companies are competing to develop 120+ pipeline drugs for non-small cell lung cancer (NSCLC), with approximately 30+ drugs in late-stage development. The competitive landscape is driven by precision oncology advances, including next-generation targeted agents and immunotherapy combinations. Recent FDA approvals and designations highlight innovation in treating EGFR-mutated, ALK-positive, and other biomarker-selected NSCLC populations.

Over 90 pharmaceutical companies are actively developing more than 100 pipeline psoriasis drugs across various clinical stages. Key players including Takeda, Can-Fite BioPharma, Oruka Therapeutics, and others are advancing promising therapies with novel mechanisms of action such as TYK2 inhibitors and IL-23 inhibitors. Recent developments include positive Phase III results from Alumis and Takeda, and regulatory progress from multiple companies, indicating robust innovation in the psoriasis treatment landscape.

The US eosinophilic esophagitis market is projected to grow at 13.2% CAGR through 2036, driven by increased disease awareness, standardized diagnostics, and high relapse rates. The market was valued at $647 million in 2025, with emerging therapies from major pharmaceutical companies expected to transform the treatment landscape, including TSLP inhibitors, glucocorticoid receptor agonists, and immunomodulators.

The Crohn's Disease therapeutics market across eight major markets is projected to grow from $9.5 billion to $13.8 billion by 2032 at a CAGR of 3.9%, driven by approvals of 8 pipeline, generic, and biosimilar therapies. Novel mechanisms of action and emerging treatments will reshape the competitive landscape, with key opportunities in strategic licensing and partnerships.

Takeda Pharmaceutical has terminated its collaboration with Denali Therapeutics on DNL593, a progranulin replacement therapy for frontotemporal dementia. The decision is strategic and not related to safety or efficacy concerns. Denali regains full ownership and control of the therapy, with plans to report Phase 1/2 trial results by end of 2026. Denali shares fell 3.73% on the news.

Eli Lilly announced a $3 billion investment in China over the next decade, with its obesity drug Mounjaro added to China's state health insurance reimbursement list. However, the company faces a setback as the U.S. Supreme Court allowed a multibillion-dollar class action lawsuit to proceed against Eli Lilly and Takeda Pharmaceutical regarding inadequate risk disclosures for the diabetes drug Actos. LLY shares were up 0.75% at $913.46.

A market research report projects growth in the Feiba VH market through 2035, driven by increasing hemophilia diagnoses, rising healthcare expenditure, expanding surgical procedures, and personalized hemophilia management. North America leads the market while Asia-Pacific is expected to experience the fastest growth. Tariffs are influencing costs but encouraging domestic investment in coagulation therapies.

Takeda Pharmaceutical's stock declined 0.64% despite positive Phase 3 trial results for Entyvio (vedolizumab) in pediatric ulcerative colitis patients. The KEPLER trial showed 47.3% of participants achieved clinical remission at week 54, with additional positive secondary endpoints. Technical analysis shows mixed momentum with neutral RSI but bearish MACD signals.

The global blood plasma derivatives market is expected to double from $52.16 billion in 2025 to $104.30 billion by 2033, growing at a 9.08% CAGR. Growth is driven by increasing immune deficiencies, hematological disorders, and neurological conditions, with immunoglobulins representing 41.28% of the market. North America leads with 39.57% market share, while Asia-Pacific is the fastest-growing region at 10.89% CAGR.

The FDA granted Breakthrough Therapy Designation to Johnson & Johnson's Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for treating advanced, HPV-unrelated head and neck squamous cell carcinoma in adults. The drug is being evaluated in combination with Merck's Keytruda in an ongoing Phase 3 trial. Additionally, J&J extended its contract with Trellus Health for patient support services through mid-2026.

The global anti-obesity drugs market is estimated at US$22.52 billion in 2026 and is projected to grow at a CAGR of 24.2% to reach US$195.99 billion by 2036, driven by rising obesity rates, improved clinical efficacy of GLP-1 and multi-agonist therapies, and broader recognition of obesity as a chronic disease. However, US trade tariffs are adding cost pressures to pharmaceutical supply chains.

Takeda Pharmaceutical reported Q3 2025 adjusted net profit of 235 billion yen ($1.53B), missing EPS expectations of 55 cents at 47 cents. Sales declined to $7.60B, below consensus of $8.53B, primarily due to generic erosion of Vyvanse for ADHD. Despite the Neuroscience revenue drop of 23.6%, the company raised its 2025 profit guidance citing cost discipline and FX tailwinds. Core operating profit jumped 16.1% to 332.4 billion yen.